Oral Polypodium Leucotomos for Melasma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01162850 |
Recruitment Status :
Completed
First Posted : July 15, 2010
Last Update Posted : August 5, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary Objective: To determine whether there is improvement in the melasma of participants taking oral Polypodium Leucotomos Secondary Objective: To determine whether oral Polypodium Leucotomos is well tolerated in study subjects with melasma.
To determine whether treatment with Polypodium Leucotomos improves the health-related quality of life.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melasma | Dietary Supplement: Polypodium Leucotomos Dietary Supplement: Placebo | Not Applicable |
Polypodium Leucotomos is a fern, also known as Calaguala used by the natives of northern Honduras as a treatment against malignant tumors Used in Spain and Central America for the treatment of psoriasis, atopic dermatitis and repigmentation of vitiligo.
Oral Polypodium Leucotomos is safe and effective in patients with melasma.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 21 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Double-Blind Placebo Controlled Study Evaluating the Effectiveness and Tolerability of Oral Polypodium Leucotomos in Patients With Melasma |
Study Start Date : | May 2008 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | June 2009 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Polypodium Leucotomos
Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
|
Dietary Supplement: Polypodium Leucotomos
Oral capsule at 240 mg taken twice a day for 12 weeks |
Placebo Comparator: Placebo
Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
|
Dietary Supplement: Placebo
240 mg Placebo taken orally twice daily created by company which manufactured active ingredient |
- Melasma Area and Severity Index (MASI) [ Time Frame: Day 0, Week 4, Week 8, Week 12 ]The following equation is used to determine the MASI score: MASI = .3A(D+H) [forhead] + .3A(D+H)[right malar] + .3A(D+H)[left malar] + .1A(D+H)[chin]; A = area, D = darkness, and H = homogeneity. Area is based on percentage of the region covered by melasma using a 1-6 scale. Darkness is determined on a 0-3 scale. Homogeneity is based on a 0-4 scale.
- Patient Assessment [ Time Frame: Week 4, Week 8, Week 12 ]Subject critiqued their melasma as either getting worse, showing no improvement, mild improvement or as showing marked improvement upon using the treatment.
- Evaluation of Photographs [ Time Frame: Post-Week 12 ]Photos were evaluated using the grading of worse, no improvement, mild improvement or marked improvement comparing week 12 to baseline.
- Adverse Events [ Time Frame: Week 4, Week 8, Week 12 ]Recorded any and all adverse events that occurred even if it was unlikely that it was associated with the study product.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy female subjects 18-50 years of age.
- Female subjects with epidermal melasma.
- Female subjects of child-bearing potential must have been willing to use an acceptable form of birth control for the duration of the study.
- Subjects with Fitzpatrick skin types II, III, & IV
- Subjects enrolled in this trial had a 2 week washout period if on prior treatment for melasma.
Exclusion Criteria:
- Pregnant or lactating
- Dermal Melasma
- Hormonal therapies less than or equal too 4 weeks prior to study
- Use of photosensitizing medications
- Simultaneous use of any form of treatment for melasma
- Subjects who were concurrently receiving light therapies
- Subjects who were unwilling to limit the amount of sun exposure
- Simultaneous ( or past 30 day) participation in a clinical research study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01162850
United States, Florida | |
University of Miami Cosmetic Center | |
Miami, Florida, United States, 33140 |
Principal Investigator: | Heather Woolery-Lloyd, MD | University of Miami |
Responsible Party: | Heather Woolery-Lloyd, MD, University of Miami |
ClinicalTrials.gov Identifier: | NCT01162850 |
Other Study ID Numbers: |
20070050 |
First Posted: | July 15, 2010 Key Record Dates |
Last Update Posted: | August 5, 2011 |
Last Verified: | July 2008 |
Melasma |
Melanosis Hyperpigmentation Pigmentation Disorders Skin Diseases |